Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases

Status unconfirmed · Phase 2

Conditions studied: Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer

In brief

RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent malignant gliomas, primary CNS lymphoma, or brain metastases.

Key facts

Study ID

NCT00276783

Run by

Northwestern University

People needed

31

Starts

2005-11-01

Expected to finish

2022-12-01

Last updated by the study team

2020-03-05

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hematology-Oncology Associates of Illinois — Chicago, Illinois, United States
• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.